StockData
Marker Therapeutics, Inc. logo

Marker Therapeutics, Inc. (MRKR) stock

MRKRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 6/30
$0.83−0.04 (-4.76%)

Close on Nov 16, 2026Market cap $13.82MP/E –Yield –

Earnings

Marker Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q3 FY2025
$1.23M
-36.0% on a year earlier
EPS, Q3 FY2025
-$0.12
-$0.26 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Marker Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2025ended Dec 31, 2025Mar 19, 2026during market hours–––Release
Q3 FY2025ended Sep 30, 2025Nov 14, 2025before the open$1.23M-36.0%-$0.12Release
Q4 FY2024ended Dec 31, 2024Mar 31, 2025before the open–––Release
Q3 FY2024ended Sep 30, 2024Nov 14, 2024during market hours$1.93M+647.7%-$0.26Release
Q2 FY2024ended Jun 30, 2024Aug 14, 2024during market hours–––Release
Q1 FY2024ended Mar 31, 2024May 15, 2024during market hours$1.24M–-$0.27Release
Q4 FY2023ended Dec 31, 2023Mar 26, 2024during market hours–––Release
Q3 FY2023ended Sep 30, 2023Nov 9, 2023during market hours$257.61K-93.5%-$0.34Release
Q2 FY2023ended Jun 30, 2023Aug 14, 2023during market hours$762.66K-3.5%$0.29Release
Q4 FY2022ended Dec 31, 2022Mar 22, 2023before the open–––Release
Q3 FY2022ended Sep 30, 2022Nov 10, 2022during market hours$3.95M–-$0.08Release
Q2 FY2022ended Jun 30, 2022Aug 11, 2022during market hours$790.51K–-$0.11Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Marker Therapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Marker Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Marker Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. News
  2. Results
  3. Results
  4. News
  5. News
  6. Update
  7. Update
  8. Update
  9. News
  10. News
  11. Results
  12. News
  13. News
  14. News
  15. Results

See a number that looks wrong?